Compare Dominion Energy Inc (D) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Dominion Energy Inc trades at $61.71 (market cap $54.31B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.3× Dominion Energy Inc's market cap, and Dominion Energy Inc pays a 4.32% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| D | VRTX | |
|---|---|---|
Market Cap | $54.31B | $127.55B |
Volume | 6,944,775 | 1,487,944 |
Sector | Utilities | Health |
52-Week High | $71.67 | $557.96 |
52-Week Low | $57.08 | $407.37 |
Typical Hold Time | 76 Days | 120 Days |
Enterprise Value | $108.43B | $121.68B |
Dividend Yield | 4.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $61.53, down 0.76% on the day, with a bearish technical signal driven by moving averages and ADX. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains solid profitability with a net income margin of 13.99%. Recent news highlights a proposed merger with NextEra Energy, which could reshape its strategic direction.
The stock offers a consensus price target of $71.56, implying potential upside, supported by a dividend yield. Key risks include execution of the merger, high debt levels, and interest rate sensitivity. Analyst sentiment is mixed with a Hold majority, reflecting cautious optimism amid transformative corporate actions.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
